Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer. The company has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-551-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.11 million
Profitability
Miscellaneous
Employees561
OptionableOptionable
Radius Health (NASDAQ:RDUS) Frequently Asked Questions
What is Radius Health's stock symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
How were Radius Health's earnings last quarter?
Radius Health Inc (NASDAQ:RDUS) announced its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($1.09) EPS for the quarter, beating the Zacks' consensus estimate of ($1.26) by $0.17. The biopharmaceutical company earned $27.70 million during the quarter, compared to the consensus estimate of $26 million. Radius Health had a negative return on equity of 140.79% and a negative net margin of 346.67%. The business's revenue for the quarter was up 105.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.31) earnings per share. View Radius Health's Earnings History.
When is Radius Health's next earnings date?
What guidance has Radius Health issued on next quarter's earnings?
Radius Health updated its FY 2019 earnings guidance on Thursday, November, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $155-175 million, compared to the consensus revenue estimate of $166.66 million.Radius Health also updated its FY 2018 guidance to EPS.
What price target have analysts set for RDUS?
8 brokerages have issued 12 month price objectives for Radius Health's shares. Their forecasts range from $25.00 to $59.00. On average, they expect Radius Health's stock price to reach $48.1429 in the next twelve months. This suggests a possible upside of 174.9% from the stock's current price. View Analyst Price Targets for Radius Health.
What is the consensus analysts' recommendation for Radius Health?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Radius Health.
What are Wall Street analysts saying about Radius Health stock?
Here are some recent quotes from research analysts about Radius Health stock:
- 1. According to Zacks Investment Research, "Radius got a boost with the approval of lead drug Tymlos. Sales of Tymlos continue to gain traction. Total prescriptions accounted for 22% of total U.S. anabolic osteoporosis market (based on Patient Months on Therapy, TRx PMOT) in the quarter. However, Radius suffered a setback when the CHMP communicated a negative trend vote for the MAA following a re-examination procedure of lead drug Tymlos. Thereafter, the CHMP communicated that it maintained its negative opinion on the MAA at its formal final vote. While the market for postmenopausal osteoporosis provides significant commercial potential, it is pretty crowded given the presence of products like Amgen’s Prolia and Lilly’s Forteo. Shares have underperformed the industry in the last six months." (1/17/2019)
- 2. Cantor Fitzgerald analysts commented, "TYMLOS Growing the Market. RDUS reported 1Q18 sales of $14.5 mln, up from $7.7 in the prior quarter. The launch is modest, which is not surprising given the specialty market and reimbursement/coverage ramp. What is a positive dynamic, in our view, is the market growth overall, with TYMLOS both capturing market share and growing the market overall for anabolics." (5/11/2018)
Has Radius Health been receiving favorable news coverage?
News coverage about RDUS stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Radius Health earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the next few days.
Who are some of Radius Health's key competitors?
Some companies that are related to Radius Health include Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Endo International (ENDP), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), Mirati Therapeutics (MRTX) and Opko Health (OPK).
Who are Radius Health's key executives?
Radius Health's management team includes the folowing people:
- Mr. Jesper Høiland, Pres, CEO & Director (Age 58)
- Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 46)
- Mr. Brent Hatzis-Schoch J.D., Sr. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Brian Nicholas Harvey, Advisor (Age 57)
- Dr. Stavros C. Manolagas M.D., Ph.D., Co-Founder and Member of the Scientific Advisory Board
Who are Radius Health's major shareholders?
Radius Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.03%). Company insiders that own Radius Health stock include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland, Jose Carmona and Joseph Francis Kelly. View Institutional Ownership Trends for Radius Health.
Which major investors are buying Radius Health stock?
RDUS stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Radius Health stock in the last two years include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland, Jose Carmona and Joseph Francis Kelly. View Insider Buying and Selling for Radius Health.
How do I buy shares of Radius Health?
Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Radius Health's stock price today?
One share of RDUS stock can currently be purchased for approximately $17.51.
How big of a company is Radius Health?
Radius Health has a market capitalization of $771.90 million and generates $22.11 million in revenue each year. The biopharmaceutical company earns $-254,230,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Radius Health employs 561 workers across the globe.
What is Radius Health's official website?
How can I contact Radius Health?
Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]
MarketBeat Community Rating for Radius Health (NASDAQ RDUS)
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
